摘要
随着新型冠状病毒肺炎(COVID-19)在国内快速爆发,国家卫生健康委员会办公厅和国家中医药管理局办公室推出不同的诊疗方案。目前根据COVID-19危重症患者的临床特征及中医辨证认为气阴两虚证为主要证型之一,生脉散为备选中成药。注射用益气复脉(冻干)是生脉散的现代制剂,对COVID-19的可能病理过程及注射用益气复脉用于心血管疾病的COVID-19治疗的药效作用及临床应用可行性进行了探讨,以期为COVID-19的中医治疗提供参考。
As the rapid outbreak of epidemic novel coronavirus pneumonia(COVID-19)in China,National Health Commission of People’s Republic of china and National Administration of Traditional Chinese Medicine have launched different programs of diagnosis and treatment.Currently,combining the clinical characteristics of critically patients,the syndrome differentiation of traditional Chinese medicine maintain that Qi-Yin deficiency is one of the main syndrome types,and Shengmai Powder is the main alternative Chinese traditional medicine.Yiqi Fumai lyophilized Injection(YQFM)is a modern preparation derived from Shengmai Powder.In the present study,we explored the potential pathological process of COVID-19.Meanwhile,the pharmacological effects as well as the possibility of clinical application of YQFM for the treatment of COVID-19 patients with cardiovascular diseases were also evaluated.This review will provide evidences for clinicians and patients in the treatment of COVID-19 using Chinese traditional treatment.
作者
万梅绪
张燕欣
李德坤
宋美珍
鞠爱春
闫凯境
余伯阳
WAN Meixu;ZHANG Yanxin;LI Dekun;SONG Meizhen;JU Aichun;YAN Kaijing;YU Boyang(Tianjin Tasly Pride Pharmaceutical Co.,Ltd.,Tianjin 300410,China 2.Tianjin Key Laboratory of Safety Evaluation Enterprise of Traditional Chinese;Medicine Injections,Tianjin 300410,China 3.Tasly Pharmaceutical Group Co.Ltd.,Tianjin 300410,China 4.School of Traditional Chinese Pharmacy,China Pharmaceutical University,Nanjing 211198,China)
出处
《药物评价研究》
CAS
2020年第3期384-391,共8页
Drug Evaluation Research
基金
天津市科技计划项目“注射用益气复脉(冻干)标准提升成果转化”(18YFCZZC00430).
关键词
新型冠状病毒肺炎
气阴两虚
注射用益气复脉(冻干)
心血管类疾病
生脉散
novel coronavirus pneumonia(COVID-19)
Qi and Yin-tonifying
Yiqi Fumai Lyophilized Injection(YQFM)
cardiovascular disease
Shengmai Powder
作者简介
第一作者:万梅绪,女,高级工程师,从事中药注射剂安全性评价、中药药理和药物警戒研究,E-mail:wanmx@tasly.com;通信作者:闫凯境,男,博士,从事中药药事管理研究,E-mail:yk@tasly.com;通信作者:余伯阳,男,教授,博士生导师,从事中药及复方药效物质基础及作用机理研究,E-mail:boyangyucpu@163.com
